Month: November 2021

The Launch and Scale Speedometer blog series. November 26, 2021 By Andrea Taylor We are excited to announce the release of new analysis and recommendations through our initiative, the COVID Global Accountability Platform (COVID GAP), a collaboration between Duke University and the Covid Collaborative. There are a plethora of dashboards and datasets on COVID-19 response, including vaccine supply and vaccination coverage, providing detail on what is happening both globally and at the country level. However, the existence of these dashboards is not resulting in actions that meet the pressing needs. The COVID GAP pulls together key data across multiple sources to highlight the need and provide evidence-based recommendations to catalyze effective actions and share promising strategies. Our latest report focuses on the 40% and 70% vaccination coverage targets, which have been widely endorsed by global leaders…

The Launch and Scale Speedometer blog series. November 18, 2021 By Stephanie Stan [caption id="attachment_2946" align="aligncenter" width="300"] Source: WHO[/caption] Scaling Lifesaving Interventions Faster: A case study on the accelerated uptake of nOPV2, the first vaccine to receive WHO Emergency Use Listing  Widespread administration of oral polio vaccines (OPVs) has resulted in reduced incidence of polio and the eradication of wild poliovirus type 2 and type 31,2. Despite progress reducing the burden of polio globally, type 2 circulating vaccine-derived poliovirus (cVDPV2) has continued to spread, primarily through Africa and Asia1,3: in 2019, there were 366 cases of cVDPV2 globally and by 2020, this number had increased to 1,069 cases1,4,5. The novel oral polio vaccine type 2 (nOPV2)—a more genetically stable, next generation polio vaccine—was developed to prevent further spread and outbreaks of cVDPV2 throughout under-immunized populations, serving to save children from poliovirus-induced paralysis and death1. In…